Cambridge Epigenetix
- Headquarters
- London, England
- Employees
- 11–50
- Founded
- 2012
- Business Model
- B2B
- Website
- cambridge-epigenetix.com
- Total Funding
- $144.5M
- Last Round
- $88.0M Series DNov 2021
About
Cambridge Epigenetix (now rebranded as biomodal) is a life sciences tools company revolutionizing genome sequencing by enabling simultaneous genetic and epigenetic analysis from a single DNA sample. Its duet multiomics platform distinguishes multiple cytosine modifications to provide a 6-base genome view, enabling earlier and more accurate detection of cancer and other diseases through liquid biopsy and research applications.
Tech Stack
Next.js
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account